| Literature DB >> 29121102 |
Alka Mahale1, Fatma Fikri1, Khitam Al Hati1, Sami Al Shahwan1, Ibrahim Al Jadaan1, Hind Al Katan1, Rajiv Khandekar1, Azza Maktabi1, Deepak P Edward1,2,3.
Abstract
Impervious encapsulation around Ahmed glaucoma valve (AGV) results in surgical failure raising intraocular pressure (IOP). Dysregulation of extracellular matrix (ECM) molecules and cellular factors might contribute to increased hydraulic resistance to aqueous drainage. Therefore, we examined these molecules in failed AGV capsular tissue. Immunostaining for ECM molecules (collagen I, collagen III, decorin, lumican, chondroitin sulfate, aggrecan and keratan sulfate) and cellular factors (αSMA and TGFβ) was performed on excised capsules from failed AGVs and control tenon's tissue. Staining intensity of ECM molecules was assessed using Image J. Cellular factors were assessed based on positive cell counts. Histopathologically two distinct layers were visible in capsules. The inner layer (proximal to the AGV) showed significant decrease in most ECM molecules compared to outer layer. Furthermore, collagen III (p = 0.004), decorin (p = 0.02), lumican (p = 0.01) and chondroitin sulfate (p = 0.02) was significantly less in inner layer compared to tenon's tissue. Outer layer labelling however was similar to control tenon's for most ECM molecules. Significantly increased cellular expression of αSMA (p = 0.02) and TGFβ (p = 0.008) was detected within capsular tissue compared to controls. Our results suggest profibrotic activity indicated by increased αSMA and TGFβ expression and decreased expression of proteoglycan (decorin and lumican) and glycosaminoglycans (chondroitin sulfate). Additionally, we observed decreased collagen III which might reflect increased myofibroblast contractility when coupled with increased TGFβ and αSMA expression. Together these events lead to tissue dysfunction potentially resulting in hydraulic resistance that may affect aqueous flow through the capsular wall.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29121102 PMCID: PMC5679546 DOI: 10.1371/journal.pone.0187506
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Antibody markers used in the study.
| Antibody | Company (Catalogue #) | Dilution | Label target | Role in scarring |
|---|---|---|---|---|
| Collagen I | Abcam (ab 34710) | 1:500 | Extracellular Matrix component (Fibrillar) | Fiber-forming ECM components, provides structural support, remodelled during wound healing, deregulated expression causes tissue dysfunction [ |
| Collagen III | Biogenex (ab167-5M) | Ready to use | ||
| Decorin | Abcam (ab115744) | 1:100 | Extracellular Matrix component (Proteoglycan) | Natural antagonists and regulators of TGFβ activity [ |
| Lumican | USBiological (L6025) | 1:100 | ||
| Aggrecan (chondroitin sulfate proteoglycan 1) | Abcam (ab 3778) | 1:50 | Extracellular Matrix component (Proteoglycan) | Structural constituents of ECM, among other functions maintain osmotic pressure and proper collagen organization [ |
| Chondroitin sulfate proteoglycan (CSPG) | Abcam (ab 11570) | 1:50 | Extracellular Matrix component (Sulphated GAG) | Synthesized by fibroblasts, interfibrillary ECM ground substance, provides lubrication and acts as a spacer between moving collagen fibers, maintains tissue hydration, important for architecture of healing tissue provides structural and regulatory function [ |
| Keratan sulfate proteoglycan | Iowa (MZ15-S) | 1:6 | Extracellular Matrix component (Sulphated GAG) | |
| Alpha smooth muscle Actin (αSMA) | Abcam (ab7817) | 1:50 | Activated fibroblasts (Myofibroblasts) | Myofibroblasts play key role in normal wound repair and are responsible for wound modulation, wound closure through contraction, secretion of ECM and other pro-fibrotic molecules [ |
| TGFβ | Abcam (ab 66043) | 1:100 | Cellular and secreted | Growth Factor, mediator of fibrosis, controls secretion of ECM molecules [ |
Demographic data and clinical parameters of patients who underwent AGV revision and control (Tenon’s) cases.
| Capsules | Tenon’s | ||
|---|---|---|---|
| (n = 14) | (n = 8) | ||
| Age (years) | Median (Quartile) | 8 (4.75) | 24 (18) |
| Minimum—Maximum | 1–58 | 1–86 | |
| Gender | Male | 10 (71%) | 5(63%) |
| Female | 4 (29%) | 3(37%) | |
| Diagnosis | Congenital Glaucoma | 10 (71.4%) | - |
| Secondary Glaucoma | 2 (14.3%) | - | |
| Primary Open Angle Glaucoma | 2 (14.3%) | 8 (100%) | |
| Type of implant | S1 | 2 (14%) | - |
| S2 | 12 (86%) | - | |
| Preoperative Glaucoma medications | Median (Quartile) | 3 (3) | - |
| Minimum—Maximum | 2–4 | - | |
| Preoperative IOP (mm Hg) | Mean (± SD) | 38.6 (±11.6) | - |
| Interval between primary implant and revision (months) | Median (Quartile) | 13.5 (4.0) | - |
| Minimum—Maximum | 3–156 | - | |
| Thickness of capsular layers (μm) | Mean (± SD) | ||
| Inner | 444.6 (194.2) | - | |
| Outer | 393.2 (163.2) | - | |
| Duration of Follow up after revision (years) | Median (Quartile) | 7.8 (4.7) | - |
| Minimum—Maximum | 0.1–16 | - | |
| Final IOP (mm Hg) | Mean (± SD) | 22.8 (±9.5) | - |
Fig 1Histology and immunohistochemical staining of select ECM molecules.
Excised capsule around Ahmed valve (upper panel) and control tenon’s tissue (bottom panel). Haematoxylin and eosin stained sections (A and B), Collagen III (C and D), Decorin (E and F) and Lumican (G and H). * Indicates bleb cavity around Ahmed valve, O and I mark the inner and outer layers respectively. 100X magnification.
Summary of immunolabels and differences in biomarkers in inner and outer layers of the excised capsules and in control tenon’s.
| Median | 25% Quartile | KW test | KW test | ||
|---|---|---|---|---|---|
| Collagen I | Capsule outer layer | 163.8 (106–184) | 146.2 | 0.0002c | |
| n = 14 | Capsule inner layer | 177.9 (151–201) | 166.3 | 0.9 | |
| Tenon | 174.3 (149.2–205.6) | 154 | |||
| Collagen III | Capsule outer layer | 145.6 (118–173) | 129.6 | 0.0002c | |
| n = 14 | Capsule inner layer | 184 (138–216) | 165.1 | 0.004 c | |
| Tenon | 95.2 (60.7–222.3) | 66.7 | |||
| Decorin | Capsule outer layer | 132.1 (81–202) | 92.7 | 0.0003c | |
| n = 13 | Capsule inner layer | 190.9 (124–225) | 152.6 | 0.02c | |
| Tenon | 138.1 (69.7–205.4) | 102.7 | |||
| Lumican | Capsule outer layer | 146.4 (107–172) | 119.3 | 0.01c | |
| n = 12 | Capsule inner layer | 190.4 (154–214) | 166.1 | 0.01c | |
| Tenon | 150.6 (105–194) | 138.3 | |||
| Chondroitin sulfate | Capsule outer layer | 157.3 (134–188) | 143.5 | 0.0002c | |
| n = 14 | Capsule inner layer | 215.4 (169–235) | 203.3 | 0.02c | |
| Tenon | 200.7 (106.1–230.2) | 179 | |||
| Aggrecan | Capsule outer layer | 211.1 (182–240) | 197.5 | 0.01c | |
| n = 12 | Capsule inner layer | 214.4 (183–240) | 203.3 | 1.0 | |
| Tenon | 218.1 (188.0–223.1) | 204 | |||
| Keratan sulfate | Capsule outer layer | 196.3 (184–203) | 189.4 | 0.01c | |
| n = 12 | Capsule inner layer | 198.9 (191–210) | 196.4 | 0.08 | |
| Tenon | 191.8 (150.2–209.4) | 187 | |||
| αSMA | Capsule | 17 (3–50) | 11.5 | 0.02 d | |
| n = 13 | Tenon | 5.3 (2–23) | 2 | ||
| TGFβ | Capsule | 210.4 (94.5–288) | 59.0 | 0.008 d | |
| n = 10 | Tenon | 64.3 (12.3–245) | 37.5 |
All markers except αSMA and TGFβ were as graded by the Image J software in the inner and outer layers of the capsule and control tenon’s tissue. Note that a lesser value indicates greater intensity of label for these molecules. n = 10–14 cases for excised capsules as specified above for each antibody, n = 8 for control tenon’s tissue except for lumican where n = 7. Kruskal Wallis test, two sided p value was performed to validate differences in label intensity between inner and outer capsular layers (a), and between inner capsular layer and control tenon’s (b) with significantly lower expression in the inner capsular layer (c), αSMA and TGFβ are reported as manual cell counts with significantly higher positivity in the excised capsules (d).
Fig 2Immunohistochemical staining for αSMA and TGFβ.
Excised capsule around Ahmed valve (upper panel) and control tenon’s tissue (bottom panel) for αSMA (A and B), TGFβ (C and D). *Indicates bleb cavity around Ahmed valve, O and I mark the inner and outer layers respectively. 200X magnification.